{"id":"https://openalex.org/W4307583331","doi":"https://doi.org/10.1093/jncics/pkac075","title":"Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)","display_name":"Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)","publication_year":2022,"publication_date":"2022-10-29","ids":{"openalex":"https://openalex.org/W4307583331","doi":"https://doi.org/10.1093/jncics/pkac075","pmid":"https://pubmed.ncbi.nlm.nih.gov/36308441","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9678401"},"language":"en","primary_location":{"id":"doi:10.1093/jncics/pkac075","doi":"https://doi.org/10.1093/jncics/pkac075","is_oa":true,"landing_page_url":"https://doi.org/10.1093/jncics/pkac075","pdf_url":"https://academic.oup.com/jncics/article-pdf/6/6/pkac075/47172082/pkac075.pdf","source":{"id":"https://openalex.org/S2735282665","display_name":"JNCI Cancer Spectrum","issn_l":"2515-5091","issn":["2515-5091"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI Cancer Spectrum","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/jncics/article-pdf/6/6/pkac075/47172082/pkac075.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068848511","display_name":"Per Pfeiffer","orcid":"https://orcid.org/0000-0002-2925-0586","observed_orcids":["https://orcid.org/0000-0002-2925-0586"]},"institutions":[{"id":"https://openalex.org/I2801498763","display_name":"Odense University Hospital","ror":"https://ror.org/00ey0ed83","country_code":"DK","type":"funder","lineage":["https://openalex.org/I2801498763"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Per Pfeiffer","raw_affiliation_strings":["Department of Oncology, Odense University Hospital , Odense, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Odense University Hospital , Odense, Denmark","institution_ids":["https://openalex.org/I2801498763"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086903918","display_name":"Maryam B. Lustberg","orcid":"https://orcid.org/0000-0001-8559-5645","observed_orcids":["https://orcid.org/0000-0001-8559-5645"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]},{"id":"https://openalex.org/I4210165192","display_name":"Smilow Cancer Hospital","ror":"https://ror.org/05q3szf80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maryam Lustberg","raw_affiliation_strings":["Smilow Cancer Hospital and Yale Cancer Center , Yale Medicine, New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Smilow Cancer Hospital and Yale Cancer Center , Yale Medicine, New Haven, CT, USA","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472","https://openalex.org/I4210165192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008597465","display_name":"Jacques N\u00e4sstr\u00f6m","orcid":"https://orcid.org/0000-0002-7509-545X","observed_orcids":["https://orcid.org/0000-0002-7509-545X"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jacques N\u00e4sstr\u00f6m","raw_affiliation_strings":["Egetis Therapeutics AB , Stockholm, Sweden"],"raw_orcid":"https://orcid.org/0000-0002-7509-545X","affiliations":[{"raw_affiliation_string":"Egetis Therapeutics AB , Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stefan Carlsson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stefan Carlsson","raw_affiliation_strings":["Egetis Therapeutics AB , Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Egetis Therapeutics AB , Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000813954","display_name":"Anders Persson","orcid":"https://orcid.org/0000-0002-9446-6981","observed_orcids":["https://orcid.org/0000-0002-9446-6981"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anders Persson","raw_affiliation_strings":["Egetis Therapeutics AB , Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Egetis Therapeutics AB , Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078057521","display_name":"Fumiko Nagahama","orcid":"https://orcid.org/0000-0003-2891-0236","observed_orcids":["https://orcid.org/0000-0003-2891-0236"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fumiko Nagahama","raw_affiliation_strings":["Solasia Pharma K.K. , Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Solasia Pharma K.K. , Tokyo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078228530","display_name":"Guido Cavaletti","orcid":"https://orcid.org/0000-0003-4128-2406","observed_orcids":["https://orcid.org/0000-0003-4128-2406"]},"institutions":[{"id":"https://openalex.org/I66752286","display_name":"University of Milano-Bicocca","ror":"https://ror.org/01ynf4891","country_code":"IT","type":"education","lineage":["https://openalex.org/I66752286"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Guido Cavaletti","raw_affiliation_strings":["Experimental Neurology Unit, School of Medicine and Surgery, University of Milano-Bicocca , Monza, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Neurology Unit, School of Medicine and Surgery, University of Milano-Bicocca , Monza, Italy","institution_ids":["https://openalex.org/I66752286"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057158252","display_name":"Bengt L. G. Glimelius","orcid":"https://orcid.org/0000-0002-5440-791X","observed_orcids":["https://orcid.org/0000-0002-5440-791X"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Bengt Glimelius","raw_affiliation_strings":["Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073330859","display_name":"Kei Muro","orcid":"https://orcid.org/0000-0002-5572-743X","observed_orcids":["https://orcid.org/0000-0002-5572-743X"]},"institutions":[{"id":"https://openalex.org/I4210133851","display_name":"Aichi Cancer Center","ror":"https://ror.org/03kfmm080","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210133851"]},{"id":"https://openalex.org/I4405286927","display_name":"Aichi Cancer Center Hospital","ror":"https://ror.org/03kh0z432","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210133851","https://openalex.org/I4405286927"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kei Muro","raw_affiliation_strings":["Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, Japan","institution_ids":["https://openalex.org/I4210133851","https://openalex.org/I4405286927"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5008597465"],"corresponding_institution_ids":[],"apc_list":{"value":1654,"currency":"USD","value_usd":1654},"apc_paid":{"value":1654,"currency":"USD","value_usd":1654},"fwci":1.9868,"has_fulltext":true,"cited_by_count":24,"citation_normalized_percentile":{"value":0.89222002,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"6","issue":"6","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12429","display_name":"Chemotherapy-induced organ toxicity mitigation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.8450000286102295},{"id":"https://openalex.org/keywords/chemotherapy-induced-peripheral-neuropathy","display_name":"chemotherapy-induced peripheral neuropathy","score":0.9909999966621399},{"id":"https://openalex.org/keywords/neuropathy-prevention","display_name":"neuropathy prevention","score":0.9309999942779541},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.8999999761581421},{"id":"https://openalex.org/keywords/hypersensitivity","display_name":"hypersensitivity","score":0.7409999966621399},{"id":"https://openalex.org/keywords/oxidative-stress","display_name":"oxidative stress","score":0.9399999976158142},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.7960000038146973},{"id":"https://openalex.org/keywords/leucovorin","display_name":"leucovorin","score":0.9309999942779541},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4050000011920929},{"id":"https://openalex.org/keywords/trial-termination","display_name":"trial termination","score":0.5559999942779541},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.7099999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9264421463012695},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.8392859101295471},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7272825241088867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6302618980407715},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5735650658607483},{"id":"https://openalex.org/C2779804826","wikidata":"https://www.wikidata.org/wiki/Q45435667","display_name":"Folinic acid","level":4,"score":0.5645681023597717},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5561999678611755},{"id":"https://openalex.org/C2779901536","wikidata":"https://www.wikidata.org/wiki/Q945238","display_name":"Peripheral neuropathy","level":3,"score":0.5322938561439514},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.45356816053390503},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4485069513320923},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3738577663898468},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3586581349372864},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.09212294220924377},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06182202696800232},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077150","descriptor_name":"Oxaliplatin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004492","descriptor_name":"Edetic Acid","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010523","descriptor_name":"Peripheral Nervous System Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D010523","descriptor_name":"Peripheral Nervous System Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011732","descriptor_name":"Pyridoxal Phosphate","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1093/jncics/pkac075","doi":"https://doi.org/10.1093/jncics/pkac075","is_oa":true,"landing_page_url":"https://doi.org/10.1093/jncics/pkac075","pdf_url":"https://academic.oup.com/jncics/article-pdf/6/6/pkac075/47172082/pkac075.pdf","source":{"id":"https://openalex.org/S2735282665","display_name":"JNCI Cancer Spectrum","issn_l":"2515-5091","issn":["2515-5091"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI Cancer Spectrum","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9678401","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9678401","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI Cancer Spectr","raw_type":"Text"},{"id":"pmid:36308441","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36308441","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI cancer spectrum","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:sdu.dk:openaire/055eeaf3-f0b8-430b-8919-4bf950df9ca9","doi":null,"is_oa":true,"landing_page_url":"https://portal.findresearcher.sdu.dk/da/publications/055eeaf3-f0b8-430b-8919-4bf950df9ca9","pdf_url":"https://findresearcher.sdu.dk/ws/files/218277108/pkac075.pdf","source":{"id":"https://openalex.org/S4306400423","display_name":"University of Southern Denmark Research Portal (University of Southern Denmark)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177969490","host_organization_name":"University of Southern Denmark","host_organization_lineage":["https://openalex.org/I177969490"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Pfeiffer, P, Lustberg, M, N\u00e4sstr\u00f6m, J, Carlsson, S, Persson, A, Nagahama, F, Cavaletti, G, Glimelius, B & Muro, K 2022, 'Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy : Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)', JNCI Cancer Spectrum, vol. 6, no. 6, pkac075. https://doi.org/10.1093/jncics/pkac075","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:boa.unimib.it:10281/404145","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10281/404145","pdf_url":null,"source":{"id":"https://openalex.org/S4306401259","display_name":"BOA (University of Milano-Bicocca)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I66752286","host_organization_name":"University of Milano-Bicocca","host_organization_lineage":["https://openalex.org/I66752286"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1093/jncics/pkac075","doi":"https://doi.org/10.1093/jncics/pkac075","is_oa":true,"landing_page_url":"https://doi.org/10.1093/jncics/pkac075","pdf_url":"https://academic.oup.com/jncics/article-pdf/6/6/pkac075/47172082/pkac075.pdf","source":{"id":"https://openalex.org/S2735282665","display_name":"JNCI Cancer Spectrum","issn_l":"2515-5091","issn":["2515-5091"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JNCI Cancer Spectrum","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G9000905448","display_name":"Yale Clinical and Translational Science Award","funder_award_id":"UL1TR001863","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320324309","display_name":"Japanese Society of Medical Oncology","ror":"https://ror.org/03fz8dh89"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337472","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4307583331.pdf","grobid_xml":"https://content.openalex.org/works/W4307583331.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W1105997994","https://openalex.org/W2000887216","https://openalex.org/W2008846239","https://openalex.org/W2095420350","https://openalex.org/W2104476156","https://openalex.org/W2119938514","https://openalex.org/W2140315342","https://openalex.org/W2149603226","https://openalex.org/W2171662247","https://openalex.org/W2470575266","https://openalex.org/W2508351246","https://openalex.org/W2620036274","https://openalex.org/W2768996399","https://openalex.org/W2923697933","https://openalex.org/W3006201748","https://openalex.org/W3025790473","https://openalex.org/W3039296430","https://openalex.org/W3039660370","https://openalex.org/W3043680095","https://openalex.org/W3045813318","https://openalex.org/W3130133219","https://openalex.org/W3217151228","https://openalex.org/W4211121451"],"related_works":["https://openalex.org/W2890982344","https://openalex.org/W2947620332","https://openalex.org/W2912251122","https://openalex.org/W2563476361","https://openalex.org/W2768996399","https://openalex.org/W7162676584","https://openalex.org/W3190123833","https://openalex.org/W4286265320","https://openalex.org/W4322774860","https://openalex.org/W3217151228"],"abstract_inverted_index":{"BACKGROUND:":[0],"Calmangafodipir":[1],"(CaM,":[2],"PledOx)":[3],"demonstrated":[4],"efficacy":[5,38],"in":[6,13,19,43,48,53,148,178,188,257],"preventing":[7,255],"patient-reported":[8],"chemotherapy-induced":[9],"peripheral":[10],"neuropathy":[11],"(CIPN)":[12],"a":[14,152],"randomized":[15],"phase":[16,66],"2":[17,127],"study":[18],"patients":[20,49,89,112,177,218],"with":[21,51,83,90,113,186,226,231],"metastatic":[22,58,114,262],"colorectal":[23,97,115],"cancer.":[24],"The":[25,192,235],"Preventive":[26],"Treatment":[27],"of":[28,41,46,155,176,217,250],"OxaLiplatin":[29],"Induced":[30],"peripherAl":[31],"neuRopathy":[32],"(POLAR)":[33],"program":[34],"aimed":[35],"to":[36,103,121,209,240],"assess":[37],"and":[39,80,136,261],"safety":[40],"CaM":[42,105,123,126,180,227],"the":[44,179,189,248,259],"prevention":[45],"CIPN":[47,72,158,184,198,256],"treated":[50],"oxaliplatin":[52,81],"adjuvant":[54,260],"(POLAR-A,":[55],"ClinicalTrials.gov.NCT04034355)":[56],"or":[57,84,93,108,129],"(POLAR-M,":[59],"ClinicalTrials.gov.NCT03654729)":[60],"settings.":[61,263],"METHODS:":[62],"Two":[63],"randomized,":[64],"placebo-controlled":[65],"3":[67],"trials":[68,164,225],"investigated":[69],"patient-reported,":[70],"moderate-to-severe":[71,183,197],"9":[73,157,201],"months":[74],"after":[75],"beginning":[76],"folinic":[77],"acid,":[78],"5-fluorouracil,":[79],"therapy":[82],"without":[85],"CaM.":[86],"In":[87,110,151],"POLAR-A,":[88],"stage":[91,95],"III":[92],"high-risk":[94],"II":[96],"cancer":[98,116],"were":[99,117,141],"randomly":[100,118],"assigned":[101,119],"1:1":[102],"receive":[104,122],"5":[106,124,166],"\u03bcmol/kg":[107],"placebo.":[109,130],"POLAR-M,":[111],"1:1:1":[120],"\u03bcmol/kg,":[125,128,167],"RESULTS:":[131],"POLAR-A":[132],"(n":[133,138],"=":[134,139,169,173,207,212],"301)":[135],"POLAR-M":[137],"291)":[140],"terminated":[142],"early":[143],"following":[144],"unexpected":[145],"hypersensitivity":[146,221],"reactions":[147,222],"CaM-treated":[149],"patients.":[150],"combined":[153],"analysis":[154],"month":[156,200],"(primary":[159],"endpoint)":[160],"data":[161],"from":[162],"both":[163,224,258],"(CaM":[165],"n":[168,172],"175;":[170],"placebo,":[171],"176),":[174],"54.3%":[175],"group":[181],"had":[182],"compared":[185],"40.3%":[187],"placebo":[190,232],"group.":[191],"estimated":[193],"relative":[194],"risk":[195],"for":[196,254],"at":[199],"was":[202],"1.37":[203],"(95%":[204],"confidence":[205],"interval":[206],"1.01":[208],"1.86;":[210],"P":[211],".045).":[213],"A":[214],"higher":[215],"proportion":[216],"experienced":[219],"serious":[220],"across":[223],"treatment":[228],"(3.6%)":[229],"than":[230],"(0.8%).":[233],"CONCLUSION:":[234],"POLAR":[236],"clinical":[237],"studies":[238],"failed":[239],"meet":[241],"their":[242],"primary":[243],"endpoint.":[244],"These":[245],"results":[246],"highlight":[247],"challenges":[249],"targeting":[251],"oxidative":[252],"stress":[253]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-11-03T00:00:00"}